European Journal of Pharmaceutics and Biopharmaceutics最新文献

{"title":"Corrigendum to “Combination of magnetic targeting with synergistic inhibition of NF-κB and glutathione via micellar drug nanomedicine enhances its anti-tumor efficacy.” [Eur. J. Pharm. Biopharm. 155 (2020) 162–176]","authors":"Kholod A. Elhasany , Sherine N. Khattab , Adnan A. Bekhit , Doaa M. Ragab , Mohammad A. Abdulkader , Amira Zaky , Maged W. Helmy , Hayam M.A. Ashour , Mohamed Teleb , Nesreen S. Haiba , Ahmed O. Elzoghby","doi":"10.1016/j.ejpb.2025.114912","DOIUrl":"10.1016/j.ejpb.2025.114912","url":null,"abstract":"","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"218 ","pages":"Article 114912"},"PeriodicalIF":4.3,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145502845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxygenated collagenase nanoliposomes for deep photodynamic therapy via remodelling the tumor extracellular matrix","authors":"Xinyi Xu ,&nbsp;Jianhua Han ,&nbsp;Xuefang Lou ,&nbsp;Xiaoling Xu ,&nbsp;Yongzhong Du","doi":"10.1016/j.ejpb.2025.114925","DOIUrl":"10.1016/j.ejpb.2025.114925","url":null,"abstract":"<div><div>Melanoma is highly aggressive and remains difficult to treat. Traditional treatment options often result in damage to normal tissues and a high rate of recurrence. Conventional photodynamic therapy (PDT) is limited by poor light penetration, oxygen depletion, and extracellular matrix (ECM) barriers. In this study, we developed an acid-responsive liposome system that co-loads indocyanine green (ICG, a photosensitizer) and 1-bromoperfluorooctane (PFOB) modified with collagenase (Col-LIP-(ICG + PFOB)) to facilitate the degradation of the tumor extracellular matrix and enable near-infrared (NIR)-triggered PDT. Our findings demonstrated that Col-LIP-(ICG + PFOB) effectively degrades the tumor extracellular matrix via collagenase, resulting in increased accumulation of the formulation within the tumor. Upon NIR irradiation, ICG produced reactive oxygen species and heat, while PFOB provided supplemental oxygen and collagenase degraded the extracellular matrix, together contributing to enhanced antitumor efficacy. In melanoma models, this system significantly inhibited tumor growth and reduced HIF-1α levels. In conclusion, this study offers a novel strategy to increase the efficacy of PDT in the treatment of melanoma.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"218 ","pages":"Article 114925"},"PeriodicalIF":4.3,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145511950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A strategy to prevent ciprofloxacin induced corneal toxicity","authors":"Parag Roy,&nbsp;Oisín N. Kavanagh","doi":"10.1016/j.ejpb.2025.114933","DOIUrl":"10.1016/j.ejpb.2025.114933","url":null,"abstract":"<div><div>Every month thousands of patients are treated with ocular ciprofloxacin, yet crystalline deposits form on the surface of the cornea in one in ten patients. This occurs due to a pH shift when the formulation is instilled onto the eye, since ciprofloxacin formulations are buffered to pH 4.5 to keep the drug in solution, whereas the tear pH is around 7. We deconstruct the formulation and the chemical pathophysiology of this condition to enable the selection of inhibitors that can derisk corneal toxicity. Through <em>in vitro</em> and <em>ex vivo</em> models we show that some structurally similar fluoroquinolones (levofloxacin and ofloxacin) can successfully inhibit the nucleation of ciprofloxacin. In contrast, other fluoroquinolones like norfloxacin can promote the formation of a less soluble ciprofloxacin–norfloxacin complex, increasing the risk of corneal deposition. We further identify that mannitol, a common excipient in marketed ophthalmic formulations, accelerates nucleation and could promote the risk of crystallisation. These findings identify both beneficial and counterproductive formulation components and define a practical anticrystal engineering strategy to prevent ciprofloxacin-induced ocular precipitation. We anticipate that this study may inspire further work designing nucleation inhibitors for transient, high supersaturation conditions such as those seen regularly during drug delivery.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"218 ","pages":"Article 114933"},"PeriodicalIF":4.3,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145511862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of design strategies for active targeted drug delivery systems for pancreatic cancer","authors":"Aysha Rahmatulla ,&nbsp;Xiaoling Bi ,&nbsp;Ping Wang ,&nbsp;Xueni Wang ,&nbsp;Shuangshuang Li ,&nbsp;Xinran Zhang ,&nbsp;Xiaofang Qiao ,&nbsp;Yuzhou Chen","doi":"10.1016/j.ejpb.2025.114915","DOIUrl":"10.1016/j.ejpb.2025.114915","url":null,"abstract":"<div><div>Pancreatic cancer (PC) is frequently referred to as the “king of cancers” due to its high mortality rate and poor prognosis. Chemotherapy drugs of a traditional nature are confronted with a multitude of challenges, including poor water solubility, low bioavailability, significant toxic side effects, and poor patient tolerance. This article provides a comprehensive review of the epidemiological and pathophysiological features of PC. The review also highlights the key antigens and receptors that are overexpressed in PC cells, including antigens such as TROP2, MSLN, MUC, and CA19-9. Furthermore, the article covers receptors like EGFR, TfR, integrins, GPCRs, IGF, GPC1, TF, and MET. The text introduces current pancreatic cancer treatment drugs, including gemcitabine, tegafur, and albumin-bound paclitaxel. The text also discusses targeted drug delivery carriers for PC, including liposomes, carbon nanotubes, exosome, polymer micelles, nanoparticles, nanocrystals, and hydrogel-encapsulated nanoparticles. The review offers a concise overview of the antibodies and ligands employed in active targeted drug delivery systems for PC, including hRS7, αTROP2, MF-T, TAB004, HzMUC1, as well as ligands such as EGF, GE11 peptide, Tf, tTR14, XQ-2d, cNGQ, α5β1-targeted peptide, IGF1, and SDC1. The therapeutic effects and prospects of combining active targeting strategies with photothermal therapy, immunotherapy, and gene editing technology are discussed in this paper.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"218 ","pages":"Article 114915"},"PeriodicalIF":4.3,"publicationDate":"2025-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145494991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A bedside-savior for insomnia and anxiety disorders: melatonin/buspirone hydrochloride compound oral fast-dissolving film","authors":"Xiaoyan Liu ,&nbsp;Chenxiao Chu ,&nbsp;Qianru Lu ,&nbsp;Xinlu Song ,&nbsp;Mingyang Wu ,&nbsp;Jingxin Gou ,&nbsp;Haibing He ,&nbsp;Tian Yin ,&nbsp;Xing Tang ,&nbsp;Xiwei Jiang ,&nbsp;Yu Zhang","doi":"10.1016/j.ejpb.2025.114930","DOIUrl":"10.1016/j.ejpb.2025.114930","url":null,"abstract":"<div><div>Insomnia and anxiety disorders are highly prevalent conditions that significantly impair daily functioning. Notably, a bidirectional relationship exists between these two disorders: heightened cortical excitability secondary to anxiety disrupts sleep onset mechanisms, while prolonged sleep insufficiency impairs prefrontal cortical regulation of emotional processing, thereby exacerbating anxiety symptoms. This creates a vicious cycle that worsens both conditions. To address this clinical challenge, we developed a combination therapy using two pharmacological agents with complementary mechanisms of action. Given the potential adverse neurological effects associated with conventional anxiolytics and hypnotics, we specifically selected two short-acting drugs with favorable safety profiles: melatonin and buspirone hydrochloride. To address insomnia accompanied by anxiety, we have designed and prepared a Bedside-savior:a compound oral fast-dissolving film containing melatonin and buspirone hydrochloride. Unlike traditional tablets or capsules, this immediate-release film offers distinct advantages for our target patients. Since it requires no water for administration, it prevents sleep disruption caused by nighttime drinking. Its ease of use makes it ideal for children, elderly individuals, and those with swallowing difficulties. Furthermore, the medication is rapidly absorbed through the sublingual venous plexus, enabling quick onset of action to simultaneously ease anxiety and promote faster sleep initiation—all without the need to get out of bed.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"218 ","pages":"Article 114930"},"PeriodicalIF":4.3,"publicationDate":"2025-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145495015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of piperine/HPβCD-loaded PVA-coated iron oxide nanoparticles in in situ gel for enhanced retinal delivery and anti-VEGF activity","authors":"Phatsawee Jansook ,&nbsp;Hay Man Saung Hnin Soe ,&nbsp;Theingi Tun ,&nbsp;Hay Marn Hnin ,&nbsp;Supakarn Chamni ,&nbsp;Rathapon Asasutjarit ,&nbsp;Sarawut Lapmanee ,&nbsp;Narumol Bhummaphan ,&nbsp;Charoenchai Puttipanyalears ,&nbsp;Sakkarin Bhubhanil ,&nbsp;Anjaree Inchan ,&nbsp;Natthawut Charoenphon ,&nbsp;Yi Lu ,&nbsp;Wei Wu","doi":"10.1016/j.ejpb.2025.114931","DOIUrl":"10.1016/j.ejpb.2025.114931","url":null,"abstract":"<div><div>Piperine (PIP) is a potential therapeutic agent for retinal diseases; however, its poor aqueous solubility limits its ocular bioavailability. To overcome this limitation, a novel nanocarrier system was fabricated through the adsorption of PIP/hydroxypropyl-β-cyclodextrin (HPβCD) inclusion complexes onto the surface of polymer-stabilized iron oxide nanoparticles (IONs), which were then incorporated into an <em>in situ</em> gelling formulation. Three hydrophilic polymers, i.e., polyethylene glycol, poloxamer 407, and polyvinyl alcohol (PVA) were used as surface coatings. Among these, PIP/HPβCD/PVA-IONs exhibited the highest percent entrapment efficiency (77.38 ± 2.17 %) and superior mucoadhesive properties. Ocular safety was evaluated using the hen’s egg test on chorioallantoic membrane (HET-CAM), which indicated no irritation. To further enhance ocular retention and retinal delivery, the PIP/HPβCD/PVA-IONs were incorporated into an <em>in situ</em> gel. Upon contact with simulated tear fluid, the formulation underwent a sol-to-gel transition with excellent gelling capacity and improved <em>ex vivo</em> permeation across excised porcine cornea (0.85 ± 0.07 × 10^-6 cm⋅s⁻¹) and sclera (3.16 ± 0.29 × 10^-6 cm⋅s⁻¹). <em>In vitro</em> studies on ARPE-19 retinal cells demonstrated the formulation was non-toxic at concentrations up to 50 µg/mL (&gt;70 % cell viability). Furthermore, <em>in vitro</em> and <em>in vivo</em> evaluations revealed that the formulation effectively suppressed vascular endothelial growth factor A at both the protein and mRNA levels. It also exhibited significant anti-inflammatory and anti-angiogenic effects. These findings suggest that the PIP/HPβCD-loaded IONs incorporated in <em>in situ</em> gel system offers a promising nanocarrier platform for targeted ocular drug delivery in the treatment of retinal diseases.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"218 ","pages":"Article 114931"},"PeriodicalIF":4.3,"publicationDate":"2025-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145488154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacomagnetography of floating gastroretentive systems in vivo in different prandial states evaluated by AC biosusceptometry","authors":"Gustavo Serafim Rodrigues ,&nbsp;Laís Pereira Buranello ,&nbsp;João Miguel Barboza ,&nbsp;Michael José Abílio Almeida ,&nbsp;Erick Guilherme Stoppa ,&nbsp;Priscileila Colerato Ferrari ,&nbsp;Guilherme Augusto Soares ,&nbsp;José Ricardo de Arruda Miranda","doi":"10.1016/j.ejpb.2025.114907","DOIUrl":"10.1016/j.ejpb.2025.114907","url":null,"abstract":"&lt;div&gt;&lt;div&gt;In recent decades, the development of effective therapies with minimal adverse effects has become a major challenge in the pharmaceutical field. Despite its popularity, oral administration faces limitations related to the physiological variability of the gastrointestinal tract (GIT), such as gastric emptying time, absorption window, and site of drug release. In this context, modified-release systems—especially gastroretentive drug delivery systems (GRDDS)—have gained prominence. GRDDS aim to prolong gastric retention time (GRT), facilitating controlled and localized drug release, particularly beneficial for drugs with limited absorption windows or instability in alkaline pH. This study evaluated the in vivo performance of a magnetic floating drug delivery system (MFDDS) containing metronidazole using pharmacomagnetography based on alternating current biosusceptometry (ACB) in healthy volunteers (n = 12, aged 19–21 years) under fasted and fed conditions. Results demonstrated that the prandial state significantly influenced MFDDS behavior, with food intake prolonging both the floating lag time (FLT) (105–120 min fed vs. 45–60 min fasted) and gastric retention time (GRT) (&lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mn&gt;165.0&lt;/mn&gt;&lt;mo&gt;±&lt;/mo&gt;&lt;mn&gt;32.2&lt;/mn&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt; min fed vs. &lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mn&gt;118.3&lt;/mn&gt;&lt;mo&gt;±&lt;/mo&gt;&lt;mn&gt;35.3&lt;/mn&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt; min fasted, p &lt; 0.0001). The orocecal transit time (OCTT) was similar between groups (&lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mn&gt;271.7&lt;/mn&gt;&lt;mo&gt;±&lt;/mo&gt;&lt;mn&gt;32.0&lt;/mn&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt; min fed vs. &lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mn&gt;254.2&lt;/mn&gt;&lt;mo&gt;±&lt;/mo&gt;&lt;mn&gt;44.9&lt;/mn&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt; min fasted, p &gt; 0.05), while small intestine transit time (SITT) was shorter in the fed state (&lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mn&gt;111.7&lt;/mn&gt;&lt;mo&gt;±&lt;/mo&gt;&lt;mn&gt;22.3&lt;/mn&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt; min) compared to the fasted state (&lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mn&gt;140.0&lt;/mn&gt;&lt;mo&gt;±&lt;/mo&gt;&lt;mn&gt;47.7&lt;/mn&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt; min), though not statistically significant. Pharmacokinetic parameters showed significant differences, with the fed state resulting in delayed time to maximum concentration (&lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mi&gt;Tmax&lt;/mi&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt;) (&lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mn&gt;252.0&lt;/mn&gt;&lt;mo&gt;±&lt;/mo&gt;&lt;mn&gt;52.9&lt;/mn&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt; min fed vs. &lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mn&gt;174.0&lt;/mn&gt;&lt;mo&gt;±&lt;/mo&gt;&lt;mn&gt;60.0&lt;/mn&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt; min fasted, p &lt; 0.05) but substantially higher maximum plasma concentrations (Cmax) (&lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mn&gt;11.0&lt;/mn&gt;&lt;mo&gt;±&lt;/mo&gt;&lt;mn&gt;5.7&lt;/mn&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt; µg/mL fed vs. &lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mn&gt;4.7&lt;/mn&gt;&lt;mo&gt;±&lt;/mo&gt;&lt;mn&gt;2.2&lt;/mn&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt; µg/mL fasted, p &lt; 0.05) and area under the curve (AUC360) (&lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mn&gt;2606.1&lt;/mn&gt;&lt;mo&gt;±&lt;/mo&gt;&lt;mn&gt;1825.5&lt;/mn&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt; µg·h/mL fed vs. &lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mn&gt;969.3&lt;/mn&gt;&lt;mo&gt;±&lt;/mo&gt;&lt;mn&gt;638.3&lt;/mn&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt; µg·h/mL fasted, p &lt; 0.05). The time lag before detectable plasma concentration (&lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mi&gt;Tlag&lt;/mi&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt;) was similar between groups (&lt;span&gt;&lt;math&gt;&lt;mrow&gt;&lt;mn&gt;67.5&lt;/mn&gt;&lt;mo&gt;±&lt;/mo&gt;&lt;mn&gt;21","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"218 ","pages":"Article 114907"},"PeriodicalIF":4.3,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145480837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic co-processing of heat-moisture treated resistant rice starch with HPMC and Eudragit® S100: A novel multifunctional excipient for direct compression and colon-targeted delivery","authors":"Karnkamol Trisopon ,&nbsp;Phennapha Saokham ,&nbsp;Nisit Kittipongpatana ,&nbsp;Neungreuthai Chomchoei ,&nbsp;Ornanong Suwannapakul Kittipongpatana","doi":"10.1016/j.ejpb.2025.114913","DOIUrl":"10.1016/j.ejpb.2025.114913","url":null,"abstract":"<div><div>A novel multifunctional excipient was developed based on co-processed resistant rice starch (RRS) for direct compression (DC) tablet and targeted colonic drug delivery. While rice starch (RS) is biodegradable and exhibits good compressibility for DC, its poor flowability and low resistant starch content limit its applicability in both DC and controlled-release formulations. To address these limitations, RS was modified using heat-moisture treatment (HMT) with optimal process parameters (moisture content, temperature, and treatment time) were determined through a design of experiments (DoE) approach. The optimized HMT conditions successfully increased resistant starch content by approximately fourfold compared with native RS, and enhanced the plastic deformation properties of RRS, improving its compressibility. To achieve targeted colonic release, a pH-sensitive and enzyme-degradable polymer system was incorporated. The optimized RRS was co-processed with high-viscosity HPMC and Eudragit® S100 through wet granulation to obtain a co-processed excipient (CRRS). The resulting CRRS demonstrated enhanced flowability, packing efficiency, and plastic deformation characteristics, meeting all SeDeM expert system criteria for DC suitability. The corrective excipient proportion (CP, %) indicated a high dilution capacity, supporting drug loading of up to 55 %. Tablets containing 30 % w/w 5-aminosalicylic acid (5-ASA) as a model drug, prepared by DC using CRRS, exhibited acceptable uniformity of dosage units, friability, and drug content. <em>In vitro</em> dissolution studies revealed a controlled-release pattern, achieving approximately 80 % cumulative release within 12 h. The dense matrix formed by resistant starch and functional polymers effectively restricted water penetration and enzymatic access, promoting gradual and site-specific release under colonic conditions compared with tablets lacking RRS. Release kinetics followed the Higuchi model, with <em>n</em> values suggesting an anomalous transport mechanism involving both diffusion and erosion. Overall, CRRS represents a promising multifunctional excipient combining excellent DC performance with controlled, site-specific colonic drug delivery potential, supporting the development of advanced oral dosage forms.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"218 ","pages":"Article 114913"},"PeriodicalIF":4.3,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145458013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of discrepancy in SNEDDS performance for a “brick dust” mebendazole between in-vitro and in-vivo estimation","authors":"Seito Maehara ,&nbsp;Saki Nishiyama ,&nbsp;Masato Maruyama ,&nbsp;Kazutaka Higaki","doi":"10.1016/j.ejpb.2025.114911","DOIUrl":"10.1016/j.ejpb.2025.114911","url":null,"abstract":"<div><div>Oral absorption of mebendazole (MBZ), a brick dust, was successfully improved 10 times by dosing 2% HPMCP-50 SNEDDS of MBZ co-amorphized with (+)-10-camphorsulufonic acid (CSA) (MBZ-CSA), compared with crystal powders in our previous study. However, an in-vitro non-sink dissolution study with pH3.9 acetate buffer or FaSSIF (conventional method) revealed that 2% HPMCP-50 SNEDDS of MBZ-CSA improved the dissolution of MBZ over 440 times compared to the crystal. In the current study, we assessed the reason for the large discrepancy in SNEDDS performance between in-vitro and in-vivo estimations using several novel in-vitro methods. The Sequential Gastro-Intestinal Exposure (SGIE) method, reflecting the transit from the stomach to the small intestine (GI-transit), revealed MBZ precipitation higher than that in the conventional method using FaSSIF. The Egg phosphatidylcholine-Monolayer-CHCl₃ Partition (EMCP) method, reflecting the absorption process, also indicated MBZ precipitation at early time periods greater than the conventional method. The SGIE-EMCP method, reflecting both GI-transit and subsequent absorption processes, indicated the highest precipitation of MBZ and MBZ transfer to the CHCl₃ phase less than the EMCP method. The SGIE-EMCP method also indicated that 2% HPMCP-50 SNEDDS transferred MBZ to the CHCl₃ phase significantly larger than SNEDDS without the polymer, which coincided with the in-vivo tendency.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"218 ","pages":"Article 114911"},"PeriodicalIF":4.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145437874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoparticle-based oral rinses for plaque control: A systematic review of efficacy and safety","authors":"Bakr Ahmed ,&nbsp;Fatima Ahmed ,&nbsp;Anil Kumar ,&nbsp;Mohammad Imran ,&nbsp;Mohammad Kashif Iqubal ,&nbsp;Hadeel Adel Al-Lami","doi":"10.1016/j.ejpb.2025.114910","DOIUrl":"10.1016/j.ejpb.2025.114910","url":null,"abstract":"<div><div>This systematic review analyzes clinical, preclinical, and patent literature on nano-enabled mouthwashes for plaque control. Searches were conducted across PubMed, Embase, Scopus, Web of Science, and three patent databases (Google Patents, Lens, and Espacenet) for English-language records published from January 2018 to June 2025. Eligible studies included randomized controlled trials (RCTs), other human investigations, and <em>in vitro, ex vivo</em>, or animal studies evaluating nanoparticle-based mouthrinses. Two reviewers independently extracted data, assessed bias risk using the RoB-2 tool, and rated evidence certainty with the GRADE approach. Findings were narratively summarized due to methodological differences. A total of 38 records met the inclusion criteria: 25 primary research studies (10 RCTs; 15 <em>in vitro</em>/animal) and 13 patents on nano-enabled mouthwashes. Silver nanoparticles were the most studied, followed by zinc oxide, titanium dioxide, calcium phosphate, and herbal nanoemulsions. Nano-enabled mouthwashes reduced plaque index by a pooled mean difference of 0.32<!--> <!-->(95 % CI: 0.25 to 0.39; I² = 45 %) and gingival index by a pooled mean difference of 0.27<!--> <!-->(95 % CI: 0.21 to 0.33; I² = 50 %) units, respectively, comparable to 0.12 % chlorhexidine (CHX), with fewer reports of staining or taste changes. Nanosilver rinses decreased white-spot lesions in orthodontic patients by 66 %, and titanium dioxide-based rinses halved dentine hypersensitivity scores. Preclinical studies showed ≥2-log reductions in biofilm viability, pH-triggered mineral release, and nanozyme-like catalytic activity. Thirteen patents (2003-2024) described stable nanoformulations, odour-neutralizing systems, mucoadhesive carriers, and theranostic technologies, indicating significant commercial interest. Evidence certainty was moderate for short-term plaque and gingival control but low for caries prevention and long-term safety. Nano-enabled mouthwashes show promise as alternatives to CHX, but large, long-term RCTs are needed to confirm efficacy, monitor safety, and support clinical use.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"218 ","pages":"Article 114910"},"PeriodicalIF":4.3,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}